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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not using the
LigaSure device provides any benefit in morality in patients undergoing hepatic resection
surgery.
STUDY DESIGN: Review of three English language randomized control trials published in 2007,
2009 and 2012.
DATA SOURCES: Data sources obtained for this review primary studies published in peerreviewed journals, found using PubMed.
OUTCOMES MEASURED: Patient mortality, defined as death within 30 days of the surgical
procedure.
RESULTS: The study done by Doklestic and et al had 3 patient mortalities occur. The deaths
occurred on post op days three, four and nine and were due to pulmonary embolism, acute
myocardial infarction and heart failure, respectively.8 Zero mortalities occurred in the
remaining two studies.9,10
CONCLUSIONS: The results of the studies showed that LigaSure did not provide a benefit in
mortality compared to the clamp crushing method, the cavitron ultrasonic surgical aspirator
(CUSA) method and to ultrasonic shears.
KEY WORDS: Hepatic; LigaSure; Liver; Resection
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INTRODUCTION
Liver cancer is the sixth most common cancer worldwide.1 For the year 2018, it was
estimated that 42,220 adults in the United States would be diagnosed with primary liver cancer.
It was also predicted that 30,200 deaths would occur in 2018 due to liver cancer, with about
68% of these deaths being men and 32% being women.2 Since 1980, the incidence of liver
cancer has tripled.2 From 2010-2011, the number of hospitalizations for liver cancer was
44,071.3 Based on these statistics, it is inevitable that a physician assistant or other health care
provider will encounter a patient with liver disease, no matter the subspecialty. The median
cost of hospitalization for liver resection surgery has more than doubled in the 10 years from
1997 to 2007—from $23,856 to $50,758.4 These numbers do not take into account the
additional follow up visits, costs of the diagnostic imaging studies performed prior to the
surgery or the cost of other adjunctive treatments if used. The most common etiology of
primary liver cancer is hepatocellular carcinoma (HCC).5 HCC, cholangiocarcinoma and
metastatic disease are among the most common causes of malignant hepatic tumor.5 In
reference to benign liver tumors, hemangiomas are the most common type, occurring in about
1-5% of adults. 6 Additional common types include adenomas and focal nodular hyperplasia.5
Risk factors for solid liver tumors include smoking, using oral contraceptive pills,
parasitic infections, anabolic steroid use, and non-alcoholic fatty liver disease.5 When talking
about HCC specifically, risk factors include alcohol abuse, obesity, cirrhosis, type II diabetes, and
chronic viral hepatitis. 5 Regardless of the specific disease diagnosed, solid liver tumor disease
presents with similar symptoms across all patients. Patient symptoms may include localized
abdominal pain, weight loss, early satiety, jaundice, palpable abdominal masses, or ascites.5 It is
a possibility that patients will be asympotmatic.5 During a workup of solid liver tumor diseases,
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laboratory blood work needs to be checked. Elevations in laboratory results such as serum
alpha-fetoprotein levels, liver function tests including ALT, AST and ALP levels, and bilirubin
levels support. But do not confirm, a diagnosis of a solid liver tumor.5 Prolonged PT time may be
seen as well.5 One of the first diagnostic imaging studies performed when a liver tumor is on
the differential diagnosis is an abdominal ultrasound. However, the diagnostic test of choice for
solid liver tumors is an abdominal CT with contrast.5 Alternatively an MRI can be done.5 Fine
needle biopsies can be used in order to confirm a diagnosis that was unclear from the
laboratory tests imaging studies.5 The treatment for liver tumors depend on the disease type
and its extent. For example, liver disease that has not spread past the liver or invaded the blood
stream, have surgery as a potential treatment option.7 Whereas, metastatic liver disease may
not qualify for surgical treatment.7 Procedural treatment options that do not remove portions
of the liver include trans-arterial embolization, radiofrequency ablation, and
radioembolization.7 These three treatments directly destroy the tumor by either disrupting its
blood supply or by using high frequency electricity to kill the cells.7 Surgical removal treatment
options for liver tumors include hepatic resection of the affected portion or liver
transplantation in severely damaged livers.
Liver resection has been shown to be a curative treatment for patients with some
benign and malignant liver tumors.5 One of the traditional techniques used is known as the
clamp crushing method, where the liver parenchyma is crushed by a small Kelly clamp.8 The
clamp crushing method is considered the gold standard for surgical resection.8 Another popular
technique is the Cavitron Ultrasonic Surgical Aspirator (CUSA). This technique uses ultrasonic
vibration to break down the parenchyma while simultaneously irrigating and aspirating the
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field.8 The ultrasonic shears also use vibration, as well as pressure, to denature proteins in the
parenchyma and collapse the vessels.9 The LigaSure vessel sealing system uses energy and
pressure to fuse the vessels in the liver parenchyma.9 The LigaSure vessel sealing system is
being proposed to evaluate if there is a more effective and less fatal technique for hepatic
resections in patients with hepatic tumors. This review evaluates three randomized control
trials comparing LigaSure to other current resection techniques.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not using the LigaSure
device provides any benefit in mortality patients undergoing hepatic resection surgery. The
hypothesis about the objective is that LigaSure provides more benefit in mortality than the
comparative surgical methods in adults undergoing hepatic resection.
METHODS
Three randomized control trials were selected to create this evidence based medicine
(EBM) review8–10. The population studied in these trials included adult patients who
undergoing hepatic resection surgery. The intervention in each study was the LigaSure vessel
sealing system. The study conducted by Campagnacci and et al compared LigaSure to ultrasonic
shears.9 In the study done by Doklestic and et al, compared LigaSure to the clamp crushing
method as well as to the cavitron ultrasonic surgical aspirator.8 The final study conducted by
Ikeda and et al compared LigaSure to the clamp crushing method.10 This EBM review focuses on
one specific outcome, patient mortality. The studies observed if any mortalities occurred and if
LigaSure provided a benefit in mortality compared to the comparison methods listed
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previously, depending on the study. Mortality was defined as death within 30 days of the
surgical procedure.
The three randomized control trials were selected via PubMed databases by using four
keywords; “LigaSure”, “hepatic”, “liver”, and “resection”. Each study was published in peerreviewed journals and in English. These specific articles were selected based on their relevance
to the clinical question being addressed and if the outcomes measured were patient-oriented
evidence that matters (POEMs). Inclusion criteria consisted of the articles being randomized
control trials, published after the year 2007 and that the patients were adults over the age of
18. The only exclusion criteria for this review was that the patient population could not consist
of children, under the age of 18. Table 1 displays the demographics and characteristics of each
randomized control trial selected for this EBM review. P-values were used as a statistic in each
study as well as an additional statistic for continuous data. The statistic used in the study
conducted by Campagnacci and et al was the unpaired student t-test.9 In the study done by
Doklestic and et al, two statistics were used; ANOVA and Kruskal-Wallis.8 The Wilcoxon rank
sum test was the statistic used in the study done by Ikeda and et all.10
Table 1: Demographics & characteristics of included studies
Study
Type #
Age
Inclusion criteria
Exclusion
Pts (yrs)
criteria
Campagnacci
(2007)2

RCT

24

39-81

All eligible hepatic
resection patients
enrolled during a
21 month period

Cirrhosis,
Child-Pough
B-C
classification,
pre-operative
concrete
suspicion of
extrahepatic
disease or
multiple

W/D Intervention
s
0

EBVS
LigaSure vs.
ultrasonic
shears for
hepatic
resections
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Doklestic
(2012)8

RCT

60

Avg
age:
57.88
+
SD
(15.83)

Hepatectomy for
benign and
malignant liver
tumors in patients
with adequate
functional reserve
of the heart, lungs
and kidneys.

Ikeda
(2009)1

RCT

120

20-85

Patients 20-85 y.o.
scheduled to
undergo hepatic
resection of some
benign or
malignant
hepatobiliary
disease and
acceptable
coagulation
profile (platelet
count > 5 x 104/ul,
prothrombin time
activity > 50%,
bleeding time < 5
minutes

0

hepatic
disease that is
not
amendable to
complete
curative
resection, ASA
greater than
stage III
Cirrhosis
0

Other
0
malignant
diseases, bilioenteric
reconstructio
n cases,
impossibility
of inflow
occlusion, and
living donors
of grafts for
liver
transplantatio
n

LigaSure vs.
clamp crush
technique
vs. CUSA for
liver
resection

Vessel
sealing
system
LigaSure vs.
clamp
crushing
method for
liver
transection

OUTCOMES MEASURED
For this EBM review, the primary outcome measured was mortality of the patient.
Mortality was defined as death of the patient within 30 days of the hepatic resection surgical
procedure.
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RESULTS
For this EBM review, three randomized control trials that compared the LigaSure vessel
sealing system to various different dissection techniques for adult patients undergoing hepatic
resection surgeries were analyzed. Table 2 displays the mortality results organized by each
study and the dissection technique used.
Table 2: Patient mortalities compared by study and by resection technique
LigaSure
Clamp Crushing CUSA
Ultrasonic shear
9
Campagnacci
0
0
Doklestic8
1
2
0
10
Ideka
0
0
In the study done by Doklestic and et al, the patients were selected from an emergency
surgery clinic in Serbia.8 Sixty patients with hepatic tumors that were undergoing liver resection
surgery from November 2008 to August 2010 were selected for the study.8 Patients were
excluded if they had been diagnosed with cirrhosis and included “liver tumors in patients with
adequate functional reserve of the heart, lungs and kidney.”8 Thirty-nine patients in this study
had malignant liver tumors due to metastatic colorectal carcinoma, HCC, gallbladder carcinoma,
and cholangiocarcinoma.8 The remaining 21 patients had benign liver disease such as
hemangiomas, adenomas, focal nodular hyperplasia, simplex cysts and echinococcal cysts.8
Three different resection techniques were compared, LigaSure, CUSA and the clamp crushing
method. Each technique group consisted of 20 randomized patients.8 The surgeries for each
group were performed by a single operating team and were kept blinded to the patients group
assignments until they were in the operating room.8 The total mortality was 5%.8 There were no
mortalities in the group of patient that received the CUSA technique.8 Two of the three deaths
in this study occurred in the group of patient that received the clamp crushing method. Both
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deaths were due to surgical complications. One patient died from a pulmonary embolism and
the other died from an acute myocardial infarction.8 The third and final death in the study
occurred in the LigaSure group. The patient in this group who died “had a malignant cardiac
arrhythmia disorder and heart failure with previous history of cardiac disease”.8 The p-value for
mortality in this study was >0.05.8 A p-value of <0.05 was needed to be considered statistically
significant.8
The study conducted by Campagnacci and et al was comprised of 24 patients
undergoing hepatic resection for malignant or benign lesions, during a 21 month period.9
Patients were excluded if they had cirrhosis, Child-Pough B-C classification, pre-operative
concrete suspicion of extrahepatic disease or multiple hepatic disease that was not amenable
to complete curative resection, and American Society of Anesthesiologists (ASA) physical status
classification greater than stage III.9 Twenty-one of the eligible patients had malignant liver
tumors form either HCC or metastatic colorectal carcinoma.9 The remaining three patients had
benign liver tumors from hemangiomas or intrahepatic lithiasis.9 All patients completed the
study and were randomized into the LigaSure group or into the ultrasonic shears harmonic
scalpel.9 Each of the resection surgeries were performed by a surgical team who had previously
conducted at least 50 hepatectomies, as well as supervised by two expert surgeons.9 The two
expert surgeons were blinded to the group assignments up until the day of the surgery.9 There
was no mortality recorded for either group, see Table 2. No further statistics were given for
mortality.9
In the study performed by Ikeda and et al, there were 165 patients who were
undergoing hepatic resection surgery, at the Tokyo University Hospital, for benign or malignant
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hepatobiliary disease.10 Of those 165, 120 qualified and all completed the study.10 A majority of
the 45 patients were excluded for one of the following reasons; high risk of hemorrhage,
required an additional surgical procedure, unable to undergo inflow occlusion or refusal to
participate. All 120 patients had malignancy in the form of either primary or metastatic liver
carcinoma.10 Half of the patients were randomized into the LigaSure vessel sealing group while
the other half were randomized into the clamp crushing group.10 The results of these group
placements were not blinded to the surgical team.10 Each surgery was performed by three
consultants and three trainees.10 No mortalities in either group occurred which is shown in
Table 2. 10 The p-value was considered statistically significant at <0.05 with a 95% confidence
interval.10 There was no p-value for mortality calculated due to the fact that it did not occur.
DISCUSSION
The three randomized control trials reviewed, showed that the LigaSure vessel sealing
system, in comparison to other resection techniques, did not provide a benefit in mortality. In
fact, each technique provided similar mortality outcomes across all studies. In the United
States, about 44 million people have no health insurance, and another 38 million have
inadequate health insurance.11 Surgical procedures and hospital stays are costly even for those
with insurance coverage. Patients with hepatic tumors may not be able to afford hepatic
resection surgeries or be able to obtain follow up care. With the LigaSure instrument, there is
an additional fifty dollar fee charged for each disposable hand piece used during the
operation.10 When compared to the Kelly clamp, the cost is increased and provides no added
benefit. The study performed by Doklestic and et al, mentions that a cost analysis of the devices
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was not included.8 Future studies can address this limitation and perform this analysis to
strengthen their results.
The most common indication for hepatic resection surgery is a malignant tumor, often
being HCC.12 However, patients with intermediate HCC, advanced HCC or HCC with portal
hypertension, are not recommend to receive hepatic resection as a first line therapy due to a
higher risk of mortality.13 The studies were limited in regards to blinding. Two of the three
articles expressed how the surgeon and surgical team were blinded up until the day of the
surgery.8,9 The additional article stated that no blinding had occurred.10 In the study done by
Campagnacci and et al, based on their calculations, a sample size of 34 patients was needed to
be statistically large enough.9 This study contained only 24 patients.9 The study performed by
Ikeda and et al, containing 120 patients, stated that a sample size of 108 patients was needed
to be statistically significant.10 In the study conducted by Doklestic and et al there was no
statement made in regards to an appropriate sample size.8 Another limitation in this study was
that there was no long term follow up or focus on the long term outcomes.8
CONCLUSION
As surgical technology advances, surgical procedures must progress just as quickly. The
studies provided in this EBM review failed to prove that there was benefit in mortality with the
LigaSure vessel sealing system, when compared to other resection techniques. It is understood
that each surgery cannot be identical. Factors such as patient’s comorbid conditions, surgeon
experience and skill level, and access to certain surgical devices can impact the results of the
surgery.
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Future study is warranted to determine whether the LigaSure technique provides
benefit in patient mortality. Aside from providing a cost analysis, these studies could try to
reduce the discrepancies by setting stricter inclusion criteria. Even though this might reduce the
sample size, having patients with similar medical histories and co-morbid conditions could
strengthen the results. Since the incidence rates of liver tumor continue to increase, this
treatment technique should continue to be studied.
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